Overview

Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study

Status:
Completed

Trial end date:
2007-08-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the safety and efficacy of Gleevec (imatinib mesylate) in the treatment of idiopathic pulmonary fibrosis (IPF).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Daniels, Craig E., M.D.

Collaborator:

Novartis

Treatments:

Imatinib Mesylate